Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 3/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8368261 | 0.99 | CYP19A1 (0.42) | CYP19A1MAOAMAOBHRH3CPA1 | |
| SCHEMBL5891402 | 0.83 | MAOA (0.38) | MAOAMAOBFNTASLC6A4FNTB | |
| SCHEMBL5891921 | 0.75 | FNTA (0.56) | CYP19A1FNTAPGGT1B | |
| SCHEMBL3500035 | 0.75 | FNTA (0.47) | CYP19A1HRH3FNTAPGGT1B | |
| Hydrochloric Acid SCHEMBL8541208 | 0.74 | FNTA (0.55) | CYP19A1FNTAPGGT1B | |
| Hydrochloric Acid SCHEMBL8368377 | 0.74 | FNTA (0.46) | CYP19A1HRH3FNTAPGGT1B | |
| SCHEMBL8506342 | 0.72 | CYP19A1 (0.54) | CYP19A1HRH3CPA1FNTAPGGT1B | |
| Hydrochloric Acid SCHEMBL8505330 | 0.71 | CYP19A1 (0.53) | CYP19A1HRH3CPA1FNTAPGGT1B | |
| SCHEMBL5891785 | 0.69 | LTB4R2 (0.30) | LTB4R2 | |
| Hydrochloric Acid SCHEMBL8368376 | 0.68 | LTB4R2 (0.30) | LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989383-B1 | Method of treating cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-01-24 | — | — | US | claimed |
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | claimed |
| JP-2001524079-A | — | — | 2001-11-27 | — | — | JP | claimed |
| EP-0973396-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0986302-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-03-22 | — | — | EP | claimed |
| EP-0973396-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-01-26 | — | — | EP | claimed |
| EP-0841919-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-24 | — | — | EP | claimed |
| WO-1998054966-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-12-10 | — | — | WO | claimed |
| WO-1998044797-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | claimed |
| EP-0841919-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-05-20 | — | — | EP | claimed |
| WO-1996037204-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-11-28 | — | — | WO | claimed |
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | disclosed |
| EP-0841919-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-24 | — | — | EP | disclosed |
| EP-0841919-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1996037204-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137207-A1 | Method of treating cancer | FNTA, GGT1, NTPCR | CYP19A1 764/4885MAOA 2291/4885MAOB 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.